What is going on with PFE?
Pfizer Inc. (PFE) today announced positive top-line results from a Phase 3 study evaluating the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in adults 65 years of age or older when administered at the same time as the seasonal influenza vaccine (SIIV, Fluad Quadrivalent [adjuvanted], 2020/2021 strains).
Shares of PFE increased 0.46% to $43.24 as of Wednesday at 9:57 am.
What does this mean for Pfizer?
Pfizer's Phase 3 study found that responses elicited by PREVNAR 20 and its seasonal influenza vaccine when given together were noninferior to those elicited by the vaccines when administered one month apart. The safety profile was also similar when the vaccines were coadministered.
“We are encouraged by these results showing that these two vaccines can be administered at the same time without affecting the immune protection provided by either vaccine or changing the safety profile,” said Kathrin U. Jansen, Ph.D., SVP, and Head of Vaccine Research & Development, Pfizer.
“This study adds to the body of evidence further supporting that pneumococcal conjugate vaccines may be coadministered with influenza vaccines, this time studied with the adjuvanted influenza vaccine."
Additionally, in May 2021, Pfizer announced the initiation of Phase 3 clinical trial exploring coadministration of PREVNAR 20 and a booster dose of COMIRNATY, its Covid-19 vaccine, in adults ages 65 or older.
PFE has a Short-Term Technical Rank of 46. Find out what this means to you and get the rest of the rankings on PFE!
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
